CN103826634A - 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用 - Google Patents

4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用 Download PDF

Info

Publication number
CN103826634A
CN103826634A CN201280044613.4A CN201280044613A CN103826634A CN 103826634 A CN103826634 A CN 103826634A CN 201280044613 A CN201280044613 A CN 201280044613A CN 103826634 A CN103826634 A CN 103826634A
Authority
CN
China
Prior art keywords
patient
amino
patients
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280044613.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·P·阿南德
C·W·雷迪克
M·石
M·E·斯蒂德
E·Y·谭
Y·王
M·R·施特格特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103826634A publication Critical patent/CN103826634A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280044613.4A 2011-09-15 2012-09-07 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用 Pending CN103826634A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535142P 2011-09-15 2011-09-15
US61/535,142 2011-09-15
PCT/US2012/054046 WO2013039764A1 (en) 2011-09-15 2012-09-07 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients

Publications (1)

Publication Number Publication Date
CN103826634A true CN103826634A (zh) 2014-05-28

Family

ID=46846036

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280044613.4A Pending CN103826634A (zh) 2011-09-15 2012-09-07 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用

Country Status (12)

Country Link
US (1) US20140221389A1 (https=)
EP (1) EP2755655A1 (https=)
JP (1) JP2014526506A (https=)
KR (1) KR20140062485A (https=)
CN (1) CN103826634A (https=)
AU (1) AU2012308993A1 (https=)
BR (1) BR112014005653A2 (https=)
CA (1) CA2848210A1 (https=)
IN (1) IN2014DN02060A (https=)
MX (1) MX2014003182A (https=)
RU (1) RU2014114827A (https=)
WO (1) WO2013039764A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
AU2020345791A1 (en) * 2019-09-11 2022-03-31 Inspirna, Inc. Methods of treating cancer
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105763A2 (en) * 2003-05-27 2004-12-09 Haegerkvist Robert Per Use of tyrosine kinase inhibitor to treat diabetes
CN1711088A (zh) * 2002-11-13 2005-12-21 希龙公司 治疗癌症的方法及相关方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1711088A (zh) * 2002-11-13 2005-12-21 希龙公司 治疗癌症的方法及相关方法
WO2004105763A2 (en) * 2003-05-27 2004-12-09 Haegerkvist Robert Per Use of tyrosine kinase inhibitor to treat diabetes

Also Published As

Publication number Publication date
RU2014114827A (ru) 2015-10-20
BR112014005653A2 (pt) 2017-03-28
US20140221389A1 (en) 2014-08-07
EP2755655A1 (en) 2014-07-23
CA2848210A1 (en) 2013-03-21
JP2014526506A (ja) 2014-10-06
AU2012308993A1 (en) 2014-03-27
MX2014003182A (es) 2014-09-22
IN2014DN02060A (https=) 2015-05-15
WO2013039764A1 (en) 2013-03-21
KR20140062485A (ko) 2014-05-23

Similar Documents

Publication Publication Date Title
Tran et al. Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations
Li et al. Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia
Yap et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Galvin et al. Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib
Al-Samkari et al. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism
Rajakariar et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature
Zhang et al. Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia
Duncan et al. 18F-FDG-PET/CT imaging in an IL-6-and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib
CN103826634A (zh) 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用
Ohkubo et al. Possible case of polyarteritis nodosa with epididymitis following COVID-19 vaccination: A case report and review of the literature
Yamamoto et al. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib
Olivan et al. Theophylline is able to partially revert cachexia in tumour-bearing rats
Markovic et al. Phase II trial of KW2189 in patients with advanced malignant melanoma
CN113694205B (zh) 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用
Uckun et al. Liposomal nanoparticles of a spleen tyrosine kinase P-site inhibitor amplify the potency of low dose total body irradiation against aggressive B-precursor leukemia and yield superior survival outcomes in mice
EP2560648A2 (en) Method for treating pancreatic cancer
Friday et al. A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors
Shafie et al. Burkitt lymphoma presenting as cecum mass and spontaneous tumor lysis syndrome with hypercalcemia
US20200268703A1 (en) Medicine for treating advanced or recurrent cancer patient being non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable
Imperiale et al. Metabolic response to BRAF-MEK combination therapy in cecal neuroendocrine carcinoma with BRAFV600E mutation and refractory lactic acidosis
US20250017931A1 (en) Methods of personalizing cancer treatment
CN120983433A (zh) 一种抑制仑伐替尼耐药性的药物组合物及其在肝癌中的应用
Sarkaria et al. NCCTG Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in newly diagnosed glioblastoma multiforme patients
Gang et al. Whether AI+ CDK4/6i+ HP is suitable treatment for three positive metastatic breast cancer patient with renal insufficiency caused by type 2 diabetes
CN105902528A (zh) 一种促进人体肿瘤发生、发展的新机制

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140528